Tag Cloud
-
aging
allergens
allergies
alopecia
Alzheimer
Alzheimer's
amino acid
appetite
asthma
avian flu
back
bird flu
brain
calcium
cancer
charge
child
Clinical trials
cure
damages
device
diabetes
Diet
disabilities
disease
diseases
drugs
fat
flu
food
gene
genes
Genetic
hair
Health
Health News
heart
heart disease
ibuprofen
implantation
influence
Influenza
Insulin
intelligence
lifestyle
lungs
Medications
Medications Online
medicine
memory
men health
menopause
mortality
nerve
Neuroscience
obesity
Operations
Order Medications
Order Medications Online
pain
phosphate
postmenopause
pregnancy
psychology
researc
research
sclerosis
skin
skin cancer
social
Statins
stem cells
stomach
stomach ulcer
stroke
study
sugar levels
Surgery
Surgical
tea
treatment
treatments
weather
weight
weight loss
WHO
woman's health
women
Working
Categories
Archives
- June 2010
- March 2010
- February 2010
- December 2009
- November 2009
- October 2009
- September 2009
- November 2008
- September 2008
- August 2008
Blogroll
-
Acomplia (Rimonabant)
Acutane (Isotretinoin) Acne Treatment
MedlinePlus: Health Topics
Rimonabant (Accomplia)
Trusted-Medicine.net
WebMD – Better information. Better health
Meta
The device copes with severe asthma without drugs
November 9, 2009
The device copes with severe asthma without drugs
American scientists tested an experimental device that uses thermal energy to relieve bronchospasm in patients with severe bronchial asthma, intractable medical treatment.
As shown by one of the last stages of clinical trials, the use of Alair System – is the name of the device – a 32% reduced the incidence of severe asthma attacks and 84% of patients reduced the number of requests for emergency medical help.
In addition, patients who were treated by this device rarely took sick and miss school, and days free from asthma symptoms, they were more than those who received placebo.
The test results were presented at the 105-th international conference of the American Thoracic Society, held in San Diego (California, USA) from 15 to 20 May 2009
The principle of the Alair System is as follows: in the respiratory tract is introduced thin tube through which the high-frequency pulses are fed, heating and destroying the excess muscle tissue of the bronchioles, which prevents them from narrowing and obstruction. The procedure called bronchial thermoplastic and an outpatient.
“In bronchial asthma in the wall of the bronchioles, there are too many smooth muscle fibers, which promote the development of seizures, – explains study leader Dr. Mario Castro of the University. George Washington at St. Louis (Missouri, USA). – Our mission – to reduce their numbers” .
To participate in clinical trials, Dr. Castro and his colleagues have invited 297 patients with severe bronchial asthma from 30 hospitals in 6 countries. Two-thirds of all participants received 3 sessions of bronchial thermoplastics, the other represented the control group, in which during the procedure rf pulses were made.
Within a year after the procedure, scientists monitored the condition of patients. In 79% of subjects who passed the experimental treatment, the condition improved. According to Dr. Castro, improvement was noted in the control group, but its severity was not statistically significant. “This is a very important advance in the treatment of bronchial asthma, – said Dr. Castro, – to this day not much we can help these patients.
All patients enrolled in clinical trials, constantly taking a combination of drugs for inhalation of corticosteroids and b-agonists long-acting, but it did not give them much relief. Could also help immunomodulator omalizumab, intended for the treatment of allergic bronchial asthma, but not all patients the cause of asthma in allergy.
This fall, Alair System expects FDA approval. In Europe, bronchial thermoplastic already approved.
Long-term receiving ibuprofen and Alzheimer’s disease
November 9, 2008
Long-term receiving ibuprofen and other non-steroid drugs protects against Alzheimer’s disease
That conclusion came from researchers at Boston University in a study involving 250 thousand persons, said the journal Neurology.
Researchers under the leadership of Steven Vlad found that people who took ibuprofen for five years, more than 40% less likely to suffer senile dementia. Other NPVP have less effect – when they receive the risk of senile dementia has fallen on average by 24%, reported the scientists. Some funds from this group, in particular celexocib not have any impact on the development of dementia.
The protective effect of ibuprofen had previously been detected in animal studies, said Vlad. He noted that the admission of the drug led to a reduction of protein deposits in the brain characteristic of Alzheimer’s disease. New data confirm its role in preventing disease.
In previous studies, scientists have analyzed the relationship between the reception NPVP and dementia, but data collected by different authors, have been controversial. Vlad and his colleagues suggested that the discrepancy results linked to the uneven effects of various anti funds and were able to confirm this theory through his research.
Nevertheless, experts still can not recommend that patients use ibuprofen to prevent dementia. NPVP long-term use may cause serious side effects, including breach of kidney function and the formation of gastric ulcer, doctors warn.